Abstract [unstructured, 250 words] 16 Ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, is a cephalosporin with 17 bactericidal activity against Gram-positive organisms including methicillin-resistant 18
Introduction

[Ceftaroline PK ELF]
In plasma. Urea in plasma samples was isolated using protein precipitation with methanol. A 142 50 µL sample was centrifuged and the supernatant diluted in mobile phase (90:10 143 methanol:water). A 10 µL sample was analyzed by LC/MS-MS, using a Phenomenex Partisil 5 144 SI column (100 x 4.6 mm with 5-µm particle size), mobile phase flow rate of 0.7 mL/min under 145 isocratic conditions, and positive polarity, to monitor for urea (m/z 61 → 44), and urea-13 C, 15 N 2 146 (m/z 64 → 46). The lower limit of quantification for urea was 100 μg/mL and the upper limit 147 was 3000 μg/mL. The precision of urea calibration standards in human plasma ranged from 148 0.82% to 2.19%, while the accuracy ranged from -1.57% to 1.53%. The precision for urea 149 quality control samples ranged from 0.80% to 6.66%, and the accuracy from -5.97% to -1.60%.used a Thermo BDS Hypersil C18 column (100 x 3 mm with a 3-µm particle size), and flow rate 153 of 0.4 mL/min under isocratic conditions. The ions monitored were urea (m/z 61 → 44) and 154 urea-13C,15N2 (m/z 64 → 46). The limits of quantification for urea ranged from 0.2 μg/mL to 155 10 μg/mL. The precision of urea calibration standards ranged from 1.28% to 4.43%, while the 156 accuracy ranged from -1.86% to 4.67%. The precision for urea quality control samples rangedmixed with 20 mM ammonium formate and centrifuged again. 15 µL aliquots were injected into 164 the LC-MS/MS, with a Waters Atlantis dC18 column (150 x 2.1 mm, 5-µm particle size), 165 mobile phase of 100 mM ammonium formate (pH 3.25):water:methanol:isopropyl alcohol 166 The range of quantification was 1-1,000 ng/mL for ceftaroline and 1-100 ng/mL for ceftaroline 193 fosamil and ceftaroline M-1. In BAL fluid the precision and accuracy of ceftaroline standards 194 were within 6.4% and ± 4.2%, respectively, for ceftaroline fosamil were within 8.0% and ± 195 3.9%, respectively, and for ceftaroline M-1 were within 7.7% and ± 2.7%, respectively. The 196 precision and accuracy of ceftaroline, ceftaroline fosamil, and ceftaroline M-1 quality control 197 samples were within 9.9% and ± 3.6%, 10.0% and ± 3.8%, and 9.4% and ± 7.7% (including 198 outliers), respectively. 199
Determination of pharmacokinetic parameters 200
The parameters describing the pharmacokinetics of ceftaroline, ceftaroline fosamil, and 201 ceftaroline M-1 in plasma and ELF were determined using non-compartmental analysis with Plasma PK parameters were determined for each subject. However, because only one ELF 210 sample was collected per subject, PK parameters in ELF were based on a composite 211 concentration-time profile consisting of median ELF concentrations across subjects at each of 212 the five BAL time points. 213
Safety analysis 214
Adverse events were recorded from the time of signing the informed consent form until 30 days 215 after the last dose of ceftaroline fosamil. 216
Measurements of vital signs were carried out at screening, before the start of and end of each 217 infusion, at intervals after dosing and at the end of the study. Blood and urine samples were 218 obtained at screening and at the end of the study. A physical examination and standard 12-lead 219 ECG was also completed at these time points.
ELF at 8 hours. Ceftaroline was not measurable in the ELF of the five subjects who underwent 277 BAL at 12 h. 278
Safety and tolerability 279
Three subjects withdrew from the study because of adverse events, all of which were mild to 280 moderate in intensity and resolved without treatment when ceftaroline fosamil was stopped. One 281 subject, who received ceftaroline 600 mg q12h, withdrew because of emesis after receiving two 282 full doses and one partial dose. The other two subjects both received ceftaroline 600 mg q8h: 283 one withdrew following one full and one partial dose because of emesis, light-headedness and 284 headache, and the second withdrew because of hypersensitivity (rhinorrhea and dry cough) on 285
Day 1, after receiving one partial dose of ceftaroline fosamil. 286
Treatment-emergent adverse events (TEAE) were reported for 11/26 (42.3%) subjects receiving 287 600 mg q12h and 10/27 (37.0%) subjects receiving 600 mg q8h. The most common TEAE were 288 headache (five subjects) and nausea (four subjects). No severe or serious adverse events were 289 observed data fall within the 90% prediction intervals for each dosing regimen. 328
Simulations to assess PK/PD target attainment 329
The percent of simulated subjects achieving %f T > MIC targets in plasma and ELF at MICs of 330 0.125 -2 mg/L are given in Table 4 and Table 5 , respectively. At an MIC of 1 mg/L for subjects 331 receiving 600 mg q12h, more than 98% of simulated patients would be expected to achieve a 332 target fT > MIC in plasma of 42% (Table 4) , which was associated with 1-log kill of S. aureus 333 in the murine lung infection model, and 100% of simulated patients would achieve 17% 334 fT>MIC, which was associated with stasis. Approximately 82%, 71%, and 14% of simulated 
